Daxas (Roflumilast)

What Is Daxas and What Is It Used For?

Daxas (roflumilast) is an oral anti-inflammatory medication belonging to the class of phosphodiesterase-4 (PDE4) inhibitors. It is used for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) in adults with chronic bronchitis and a history of frequent exacerbations, as an add-on to bronchodilator therapy.

Daxas contains the active substance roflumilast, which works by reducing the activity of an enzyme called phosphodiesterase-4 (PDE4). This enzyme is naturally present in the body's cells and plays a key role in regulating inflammatory processes. By inhibiting PDE4, roflumilast increases levels of cyclic adenosine monophosphate (cAMP) within inflammatory cells such as neutrophils, macrophages, and T-lymphocytes. This elevation in cAMP leads to a cascade of anti-inflammatory effects, ultimately reducing the lung inflammation that drives COPD progression.

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition characterized by persistent airflow limitation. The disease involves two main components: chronic bronchitis, which causes inflammation and excessive mucus production in the airways, and emphysema, which destroys the tiny air sacs (alveoli) in the lungs. Together, these processes lead to symptoms such as persistent cough, wheezing, chest tightness, and progressive shortness of breath. According to the World Health Organization (WHO), COPD is the third leading cause of death worldwide, affecting an estimated 380 million people globally.

Daxas is specifically indicated for patients with severe COPD (defined as FEV1 less than 50% predicted after bronchodilator use) who have the chronic bronchitis phenotype and a history of frequent exacerbations (flare-ups) despite treatment with bronchodilators. Exacerbations are episodes of acute worsening of symptoms that often require additional treatment, hospitalization, or both. Clinical trials, including the landmark REACT and RE2SPOND studies, demonstrated that roflumilast reduced the rate of moderate-to-severe exacerbations by approximately 15–20% when added to standard bronchodilator therapy.

It is important to understand that Daxas is a long-term maintenance therapy and does not provide immediate relief of symptoms. The medication works gradually to reduce underlying inflammation, and patients may need to take it for several weeks before experiencing its full therapeutic benefit. Daxas should always be used alongside other COPD medications such as inhaled corticosteroids, long-acting beta-agonists (LABAs), or long-acting muscarinic antagonists (LAMAs), not as a replacement for them.

How Does Roflumilast Work in COPD?

The pathophysiology of COPD involves a complex interplay of inflammatory cells and mediators. In patients with chronic bronchitis, the airways become chronically inflamed, leading to mucus hypersecretion, airway wall thickening, and progressive narrowing of the bronchial passages. Neutrophils, a type of white blood cell, play a particularly prominent role in COPD-associated inflammation.

Phosphodiesterase-4 is the predominant phosphodiesterase isoenzyme found in inflammatory and immune cells, including neutrophils, monocytes, macrophages, and CD4+ and CD8+ T-cells. By selectively inhibiting PDE4, roflumilast increases intracellular cAMP concentrations within these cells. Elevated cAMP activates protein kinase A (PKA), which in turn suppresses the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), and leukotriene B4 (LTB4). This targeted anti-inflammatory action helps reduce the chronic airway inflammation that underlies COPD exacerbations.

Unlike bronchodilators, which work by relaxing airway smooth muscle to provide rapid symptom relief, roflumilast addresses the underlying inflammatory component of COPD. This makes it a complementary therapy rather than a substitute for bronchodilators. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 guidelines recommend roflumilast as an add-on therapy for patients in GOLD group E (frequent exacerbators) who have the chronic bronchitis phenotype and whose exacerbations are not adequately controlled by inhaled therapies alone.

What Should You Know Before Taking Daxas?

Before starting Daxas, it is essential to inform your doctor about all medical conditions, current medications, and whether you are pregnant or breastfeeding. Several conditions and drug interactions may make Daxas unsuitable or require careful monitoring.

Contraindications

Daxas must not be taken if you have a known allergy (hypersensitivity) to roflumilast or any of the other ingredients in the tablet, including lactose monohydrate, maize starch, povidone, and magnesium stearate. Allergic reactions to Daxas, while uncommon, can include skin rash, swelling of the face, lips, tongue, or throat, and difficulty breathing. If you experience any signs of a severe allergic reaction, stop taking Daxas immediately and seek emergency medical care.

Daxas is also contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The liver plays a central role in metabolizing roflumilast, and impaired liver function can lead to significantly increased drug exposure, raising the risk of adverse effects. Patients with mild hepatic impairment (Child-Pugh A) should be treated with caution and monitored closely by their prescribing physician.

Warnings and Precautions

Body weight monitoring: Weight loss has been observed in clinical trials of roflumilast. Patients should weigh themselves regularly while taking Daxas. If you notice unintentional weight loss that is not related to changes in diet or exercise, inform your doctor. In clinical studies, weight loss of more than 10% of body weight was reported in approximately 6–10% of patients receiving roflumilast, compared with 2–3% receiving placebo. Weight typically stabilizes after the first few months of treatment, and most patients regain weight after discontinuation.

Psychiatric symptoms: Daxas is not recommended for patients with a history of depression associated with suicidal thoughts or behavior. During clinical trials and post-marketing surveillance, rare cases of suicidal ideation and behavior, including completed suicide, have been reported. Patients may also experience insomnia, anxiety, nervousness, or depressed mood. You or your caregiver should immediately inform your doctor if you notice any changes in behavior, mood, or if you develop suicidal thoughts. Patients already taking medications for psychiatric conditions may be at increased risk.

Gastrointestinal effects: During the first weeks of treatment, diarrhea, nausea, abdominal pain, or headache may occur. These are the most commonly reported adverse effects of roflumilast. In most cases, these symptoms are mild to moderate in severity and resolve within the first few weeks of continued treatment. If gastrointestinal side effects persist beyond this initial period, consult your doctor.

Conditions requiring caution: Daxas is not recommended for patients with:

• Severe immunological disorders such as HIV infection, multiple sclerosis (MS), systemic lupus erythematosus (SLE), or progressive multifocal leukoencephalopathy (PML)
• Severe acute infectious diseases such as acute hepatitis
• Cancer (except basal cell carcinoma, a slow-growing type of skin cancer)
• Severe cardiac impairment (NYHA class III or IV heart failure)

This is because there is insufficient clinical experience with Daxas in patients with these conditions. Experience is also limited in patients with a history of tuberculosis, viral hepatitis, herpes infection, or herpes zoster (shingles). Always inform your doctor if you have any of these conditions.

Pregnancy and Breastfeeding

Daxas should not be used during pregnancy. Animal studies have shown that roflumilast can cause harm to the developing fetus, including reduced fetal weight and skeletal abnormalities. If you are pregnant, think you may be pregnant, or are planning to have a baby, consult your doctor before taking this medicine. Women of childbearing potential should use effective contraception during treatment with Daxas.

It is not known whether roflumilast or its metabolites pass into human breast milk. Animal studies have demonstrated excretion into milk. Therefore, Daxas should not be used during breastfeeding. Your doctor will help you weigh the benefits of treatment against the potential risks to the nursing infant.

Children and Adolescents

Daxas should not be given to children and adolescents under 18 years of age. The safety and efficacy of roflumilast have not been established in the pediatric population, and COPD is an adult-onset disease that very rarely affects young people.

Driving and Operating Machinery

Daxas has no known effect on the ability to drive or operate machinery. However, patients who experience dizziness or vertigo (uncommon side effects) should exercise caution when driving or using machines until they know how the medication affects them.

How Does Daxas Interact with Other Drugs?

Daxas can interact with several medications that affect liver enzymes involved in its metabolism. Some drugs increase roflumilast levels (CYP1A2/2C19 inhibitors), while others decrease its effectiveness (CYP3A4/1A2 inducers). Always inform your doctor about all medications you are taking.

Roflumilast is primarily metabolized by the liver enzyme CYP3A4, with additional contributions from CYP1A2. Its active metabolite, roflumilast N-oxide, is formed via CYP3A4 and CYP1A2 and contributes significantly to the overall pharmacological activity. Therefore, medications that inhibit or induce these enzymes can substantially alter the therapeutic effect of Daxas.

Major Interactions — CYP Inhibitors

The following medications can significantly increase roflumilast exposure and may require dose adjustment or close monitoring:

Enzyme Inducers That Reduce Effectiveness

Certain medications that activate liver enzymes (enzyme inducers) can accelerate the breakdown of roflumilast, potentially reducing its therapeutic effect to clinically insignificant levels. These include:

If you are taking any of these enzyme-inducing medications, your doctor may determine that Daxas is unlikely to provide sufficient therapeutic benefit, and an alternative treatment strategy may be needed.

Immunosuppressive Agents

Inform your doctor if you are taking immunosuppressive medications such as methotrexate, azathioprine, infliximab, etanercept, or long-term oral corticosteroids. While there are no formal contraindications, the combination of Daxas with these agents has not been extensively studied. Clinical experience is limited, and potential additive effects on the immune system cannot be excluded.

Compatible COPD Medications

Daxas can safely be taken alongside other common COPD medications, including:

• Inhaled corticosteroids (e.g., budesonide, fluticasone)
• Long-acting beta-agonists — LABAs (e.g., salmeterol, formoterol)
• Long-acting muscarinic antagonists — LAMAs (e.g., tiotropium)
• Short-acting bronchodilators (e.g., salbutamol/albuterol)
• Oral corticosteroids (short courses)
• Theophylline (clinical studies showed no significant pharmacokinetic interaction, although theoretical additive PDE-inhibitory effects exist)

What Is the Correct Dosage of Daxas?

Daxas treatment follows a two-phase dosing regimen: a 28-day titration period at 250 mcg once daily, followed by a maintenance dose of 500 mcg once daily. The tablet should be swallowed whole with water at the same time each day, with or without food.

Adults

The dosing of Daxas is designed to minimize gastrointestinal side effects by gradually introducing the medication to the body:

How to take Daxas: Swallow the tablet whole with a little water. Daxas can be taken with or without food. Take your tablet at the same time each day to maintain consistent blood levels and help you remember your dose. Do not crush, split, or chew the tablet unless specifically instructed by your doctor or pharmacist.

Children

Daxas is not approved for use in children and adolescents under 18 years of age. COPD is overwhelmingly a disease of adults, and the safety and efficacy of roflumilast have not been established in the pediatric population.

Elderly

No dose adjustment is required for elderly patients. However, elderly patients may be more susceptible to certain side effects such as insomnia, diarrhea, and headache. Close monitoring during the initiation phase is advisable, particularly in patients over 75 years of age or those with multiple comorbidities.

Renal Impairment

No dose adjustment is necessary for patients with kidney problems (renal impairment). Renal elimination plays a minor role in the clearance of roflumilast and its active metabolite.

Missed Dose

If you forget to take your Daxas tablet at the usual time, take it as soon as you remember on the same day. If you do not remember until the following day, simply take your next dose at the regular time. Do not take a double dose to make up for a forgotten dose. Continue taking the medication at the regular times thereafter.

Overdose

If you take more Daxas than prescribed, you may experience the following symptoms:

• Headache
• Nausea and vomiting
• Diarrhea
• Dizziness
• Palpitations (sensation of rapid or irregular heartbeat)
• Light-headedness or feeling faint
• Clamminess and cold sweats
• Low blood pressure (hypotension)

In case of overdose, contact your doctor, pharmacist, or poison control center immediately. If possible, bring your remaining tablets and this information with you. There is no specific antidote for roflumilast; treatment is supportive and symptomatic. Hemodialysis is unlikely to be effective due to the high protein binding of roflumilast and its active metabolite.

What Are the Side Effects of Daxas?

Like all medicines, Daxas can cause side effects, although not everyone experiences them. The most common side effects include diarrhea, nausea, abdominal pain, and headache, particularly during the first weeks of treatment. Most of these effects are mild to moderate and tend to resolve as the body adjusts.

In clinical trials involving over 12,000 patients, the adverse effect profile of roflumilast was well characterized. Side effects are most likely to occur during the initiation phase and generally diminish with continued treatment. Approximately 16% of patients in clinical trials discontinued roflumilast due to adverse effects, compared with 9% in the placebo group. The 28-day low-dose titration phase was introduced specifically to reduce the incidence and severity of these initial side effects.

Allergic Reactions

Allergic reactions to Daxas are uncommon. In rare cases, allergic reactions can cause swelling of the eyelids, face, lips, and tongue (angioedema), potentially leading to difficulty breathing, drop in blood pressure, and rapid heartbeat. If you experience a severe allergic reaction (anaphylaxis), stop taking Daxas immediately and seek emergency medical attention. Bring your remaining tablets and share full details of your current medications with the treating medical team.

Managing Gastrointestinal Side Effects

The most frequently reported side effects — diarrhea, nausea, and abdominal pain — are typically transient and occur during the first few weeks of treatment. Taking Daxas with food may help reduce nausea in some patients. Staying well hydrated is important if you experience diarrhea. If these symptoms are severe or persist beyond the initial 4–6 weeks, consult your doctor, who may adjust your treatment.

Weight Changes

Weight loss is a recognized effect of roflumilast and occurred in clinical trials at a higher rate than with placebo. In the pivotal clinical studies, the mean weight loss was approximately 2 kg during the first 6 months of treatment. In most patients, weight stabilized thereafter. Patients who were underweight or had a BMI below 20 before starting treatment should be monitored more closely. Unexplained or significant weight loss should be reported to your doctor promptly.

Reporting side effects: Reporting suspected adverse reactions after a medicine has been authorized is important. It allows continued monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients are encouraged to report suspected side effects to their national regulatory authority, such as the FDA MedWatch program in the United States, the MHRA Yellow Card Scheme in the United Kingdom, or the EMA EudraVigilance system in the European Union.

How Should You Store Daxas?

Daxas does not require any special storage conditions. Store the tablets in their original packaging, at room temperature, and keep them out of the sight and reach of children.

Daxas tablets should be stored in their original blister pack to protect them from moisture and light. No specific temperature requirements apply; normal room temperature storage (below 30°C / 86°F) is appropriate. As with all medications, check the expiry date printed on the outer carton and blister strip before use. The expiry date refers to the last day of the stated month. Do not use Daxas after this date.

Keep this medicine out of the sight and reach of children. A locked medicine cabinet or high shelf is recommended.

Do not dispose of unused medicines via household waste or by flushing them down the toilet. Return unused or expired tablets to your pharmacist, who will ensure they are disposed of in an environmentally safe manner. Many countries have dedicated take-back programs for unused medications. These measures help protect the environment from pharmaceutical contamination of water sources and soil.

What Does Daxas Contain?

Each Daxas 500 microgram film-coated tablet contains 500 micrograms of the active ingredient roflumilast, along with inactive excipients in the tablet core and film coating.

Active Ingredient

Each film-coated tablet contains 500 micrograms of roflumilast.

Inactive Ingredients (Excipients)

Physical Description

Daxas 500 microgram tablets are yellow, D-shaped, film-coated tablets embossed with the letter “D” on one side. They are available in pack sizes of 10, 14, 28, 30, 84, 90, or 98 film-coated tablets. Not all pack sizes may be marketed in every country.

Related Medicines